Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 VALLON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4369909 (State or other jurisdiction of incorporation or organization) (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40034 VALLON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | --- | | 82-4369909 | incorpo ...

NASDAQ: VLON vallon-pharma.com | --- | --- | --- | --- | --- | |-------|-------|-------|-------|------------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Working to Reduce ADHD Medication Abuse | | | | | | Investor Presentation March 2021 | Forward Looking Statements 2 This presentation contains projections of, and assumptions regarding, future events reflecting our beliefs and expectations. Such events may or may not occur. Consequently, t ...